Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (XanaMIA)

April 3, 2024 updated by: Actinogen Medical

A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaMIA Phase 2b study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

220

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female aged 50 years or older, inclusive at the time of Screening.

  • Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:

    1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
    2. Mini-mental state examination (MMSE) score of 18 to 26
    3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
    4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
    5. Cognitive impairment on a symbol coding test of at least 0.5 standard deviations (SD) below the normative data at Screening.
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
  • Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
  • Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
  • Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
  • Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.

Exclusion Criteria:

  • Use of anti-amyloid or anti-tau antibody within 6 months.
  • Diagnosis of a non-AD dementia including traumatic brain injury.
  • Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
  • Participation in another clinical trial of a drug or device
  • Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
  • Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
  • Clinical diagnosis of Type I or Type II diabetes requiring insulin.
  • Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
  • Participants with a history of clinically significant drug abuse or addiction in the past 2 years
  • Evidence or history of alcohol abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food
Drug: Xanamem
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Other Names:
  • UE2343
Placebo Comparator: Placebo
Placebo tablet, to be administered orally once every morning with or without food
Drug: Placebo
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of 10 mg Xanamem on cognition
Time Frame: 36 weeks
Change from Baseline to end of treatment (EOT) in a custom global cognitive test battery (CTB). The global CTB is calculated as an average Z-score, with higher scores indicating improvement.
36 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Time Frame: 36 weeks
Incidence and severity of TEAEs
36 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of Xanamem on integrated cognitive and functional abilities
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB)
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on early impairment of daily functioning due to cognitive decline
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT on the Amsterdam Instrumental Activities of Daily Living Questionnaire - short version (A-IADL-Q-SV). Each question is given a score from 1 to 5, with higher scores indicating a better outcome.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on attention and working memory
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in an Attention Composite. Scores are calculated as an average Z-score, with higher scores indicating improvement.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on executive function
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in an Executive Function Composite. Scores are calculated as an average Z-score, with higher scores indicating improvement.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on episodic memory
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in an Episodic Memory Composite. Scores are calculated as an average Z-score, with higher scores indicating improvement.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on paper and pencil tests of cognition (visual attention and executive function)
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in Trail Making A and B Tests, measured as time taken to complete (seconds). Higher scores indicate a worse outcome.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on AD biomarker ratios
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in ratios of plasma AD biomarkers: amyloid-beta 1-42/1-40 and p-tau181/amyloid-beta 1-42.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on neuropsychiatric symptoms of AD
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT on the Neuropsychiatric Inventory (NPI) and its component scores. A total score is calculated from the frequency and severity of each behavior. Higher scores indicate a worse outcome.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem using clinicians' and participant/trial partner's global impression measures
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in the Clinician's Global Impression of Severity Scale (CGI-S). Assessment is made on a seven-point scale, with a higher score indicating a worse outcome.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem using clinicians' and participant/trial partner's global impression measures
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in the participant/trial partner's scores in the Patient's Global Impression of Change (PGI-C). Assessment is made on a seven-point scale, with a higher score indicating a worse outcome.
36 weeks (Baseline to Week 36 [EOT])
Effects of Xanamem on biomarkers of AD.
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Change from Baseline to EOT in plasma AD biomarkers. Biomarkers to be assessed are: p-tau181, p-tau217, amyloid-beta 1-40, amyloid-beta 1-42, neurofilament light, glial fibrillary acidic protein (all pg/mL).
36 weeks (Baseline to Week 36 [EOT])

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sparse PK sampling for use in PPK analysis
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Plasma Xanamem concentration (ng/mL)
36 weeks (Baseline to Week 36 [EOT])
On-treatment visit PK data to assess compliance
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Plasma Xanamem concentration (ng/mL)
36 weeks (Baseline to Week 36 [EOT])
Collection of urine for metabolite screening
Time Frame: 36 weeks (Baseline to Week 36 [EOT])
Identification of potential urine metabolites of Xanamem
36 weeks (Baseline to Week 36 [EOT])

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Actinogen Medical

Investigators

  • Study Director: Global Program Lead, Actinogen Medical Ltd

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

October 23, 2023

First Submitted That Met QC Criteria

November 5, 2023

First Posted (Actual)

November 9, 2023

Study Record Updates

Last Update Posted (Actual)

April 5, 2024

Last Update Submitted That Met QC Criteria

April 3, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACW0009

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Xanamem

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe